WALTHAM, Massachusetts, May 1, 2026
Alcresta Therapeutics, Inc. announced the publication of preclinical data evaluating its RELiZORBneo cartridge in a neonatal murine model of necrotizing enterocolitis (NEC), highlighting a potential safety benefit through modulation of disease severity. The findings, published in a peer-reviewed journal, demonstrate that pre-digestion of fats in enteral nutrition using RELiZORBneo may reduce inflammation and improve clinical outcomes, positioning the device as a promising innovation for neonatal care where digestive immaturity presents significant clinical challenges.
Preclinical Study Demonstrates Reduced Disease Severity
The study, conducted in collaboration with researchers at Boston Children’s Hospital, assessed whether RELiZORBneo could improve survival and reduce severity of NEC, a life-threatening gastrointestinal condition that primarily affects premature infants. Results showed that enteral nutrition processed through RELiZORBneo led to statistically significant improvements in clinical sickness scores, intestinal appearance, and histological severity compared to placebo. These findings suggest that pre-hydrolyzing fats before delivery may limit inflammatory responses triggered by undigested triglycerides, a known contributor to NEC pathogenesis. While improvements in survival rates and weight gain were observed, these did not reach statistical significance due to the short duration and exploratory nature of the study, indicating the need for further research.
Addressing Critical Nutritional Gaps in Neonatal Care
RELiZORBneo is specifically designed as a next-generation, miniaturized enzyme-based cartridge for use in neonates and infants requiring enteral feeding. Unlike standard formulations, the device contains immobilized lipase that breaks down fats in real time, enabling better absorption of essential nutrients. This is particularly important in neonates, where pancreatic immaturity leads to insufficient lipase production, resulting in poor fat absorption. Adequate fat digestion is essential not only for meeting caloric needs but also for supporting brain development and neurological growth, making RELiZORBneo a potentially transformative tool in neonatal nutrition management.
Advertisement
Building on Proven RELiZORB Platform
The development of RELiZORBneo builds on the success of RELiZORB®, a commercially available device that has demonstrated safety and efficacy in improving fat absorption in patients with exocrine pancreatic insufficiency (EPI), including those with cystic fibrosis and short bowel syndrome. By adapting this technology into a smaller, low-volume, and slow-flow compatible format, Alcresta aims to extend its benefits to tube-fed neonates and infants, a population with highly specific nutritional and physiological requirements. Once cleared by regulatory authorities, RELiZORBneo is expected to fill a critical gap in pediatric and neonatal enteral nutrition solutions.
Mechanistic Insight into NEC Prevention
The underlying mechanism highlighted by the study centers on the reduction of inflammation through pre-digested lipid delivery. In NEC, undigested fats can trigger intestinal inflammation, tissue damage, and systemic complications, often leading to severe morbidity or mortality. By ensuring that fats are already hydrolyzed before entering the digestive tract, RELiZORBneo may help reduce the inflammatory burden and protect intestinal integrity. This mechanistic advantage positions the device not just as a nutritional aid, but as a potential therapeutic adjunct in preventing or mitigating NEC severity.
Strategic Implications for Pediatric MedTech Innovation
The positive preclinical findings reinforce Alcresta Therapeutics’ strategy to expand its enzyme-based technology platform into new clinical indications, particularly in high-need pediatric populations. NEC remains one of the most serious and costly neonatal conditions, with limited preventive and therapeutic options currently available. The ability to improve outcomes through a non-pharmacological, device-based intervention offers a compelling advantage, especially in vulnerable populations where drug-based approaches may carry additional risks.
Path Forward and Clinical Potential
While these results are promising, further clinical studies will be required to validate efficacy and safety in human neonates. If successful, RELiZORBneo could become a standard component of enteral feeding protocols in neonatal intensive care units (NICUs), improving survival and long-term developmental outcomes. The technology also aligns with broader trends in precision nutrition and device-driven therapeutic strategies, emphasizing targeted, mechanism-based interventions.
Overall, the study positions RELiZORBneo as a high-potential innovation in neonatal MedTech, with the ability to address both nutritional deficiencies and disease mechanisms simultaneously, potentially redefining care standards for infants at risk of necrotizing enterocolitis.
Source: Alcresta Therapeutics press release
